US4758555A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method for treating convulsions and epilepsy with organic copper compounds
Assignee: International Copper Research Assn Inc
•
Filing: 1986-12-08
•
Granted: 1988-07-19
•
Expires: 2006-12-08
Abstract
Abstract Copper-dependent enzymes are required for normal brain development and function. Copper deficiency can result in pathological disorders accompanied by convulsive seizures or tremors in man and animals. The present invention is directed to a method for treating convulsions or epilepsy comprising administration of a therapeutically effective amount of an organic compound of copper having anticonvulsant activity. Those compounds include copper complexes of carboxylic acids, acylsalicylates, salicylates, amino acids, imines and known anticonvulsant and antiepileptic drugs.
Inventors
- 👤 John R. J. Sorenson
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-08 02:04
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/28; A61K31/30
Claims Analysis
Total Claims: 25
Claim 1
Independent Claim
50 words
A method of treating convulsive tremors or convulsive seizures comprising administration to a mammal of a therapeutically effective amount of an organic compound of copper having anticonvulsant activity selected from the group consisting of a copper complex of a carboxylic acid and a mixture of copper complexes of carboxylic acids.
Claim 2
Independent Claim
50 words
A method of treating convulsive tremors or convulsive seizures comprising administration to a mammal of a therapeutically effective amount of an organic compound of copper having anticonvulsant activity selected from the group consisting of a copper complex of a carboxylic acid and a mixture of copper complexes of carboxylic acids.
Claim 3
Independent Claim
46 words
A method of treating epilepsy comprising administration to a mammal of a therapeutically effective amount of an organic compound of copper having antiepileptic activity selected from the group consisting of a copper complex of a carboxylic acid and a mixture of copper complexes of carboxylic acids.
Claim 4
Independent Claim
46 words
A method of treating epilepsy comprising administration to a mammal of a therapeutically effective amount of an organic compound of copper having antiepileptic activity selected from the group consisting of a copper complex of a carboxylic acid and a mixture of copper complexes of carboxylic acids.
Claim 5
Dependent Claim
25 words
The method according to claim 1 or 2 wherein the copper complex of a carboxylic acid is a copper complex of an aliphatic carboxylic acid.
Claim 6
Dependent Claim
25 words
The method according to claim 3 wherein the aliphatic carboxylic acid is a straight chain, saturated or unsaturated, C 1 to C 19 monocarboxylic acid.
Claim 7
Dependent Claim
24 words
The method according to claim 3 wherein the aliphatic carboxylic acid is a straight or branched chain C 1 to C 7 monocarboxylic acid.
Claim 8
Dependent Claim
41 words
The method according to claim 3 wherein the copper complex of an aliphatic carboxylic acid is selected from the group consisting of: (a) Cu(II) 2 (acetate) 4 ; (b) Cu(II) 2 (valproate) 4 ; and (c) Cu(II) 2 (phenylacetate) 4 .
Claim 9
Dependent Claim
25 words
The method according to claim 1 or 2 wherein the copper complex of a carboxylic acid is a copper complex of an aryl carboxylic acid.
Claim 10
Dependent Claim
14 words
The method according to claim 7 wherein the aryl carboxylic acid is an acylsalicylate.
Claim 11
Dependent Claim
57 words
The method according to claim 8 wherein the copper complex of an acylsalicylate is selected from the group consisting of: (a) Cu(II) 2 (adamantylsalicylate) 4 ; (b) Cu(II) 2 (acetylsalicylate) 4 ; (c) Cu(II)(acetylsalicylate) 2 (dimethylsulfoxide) 2 ; (d) Cu(II)(acetylsalicylate) 2 (pyridine) 2 ; (e) Cu(II) 2 (3,5-dibromoacetylsalicylate) 4 ; and (f) Cu(II) 2 (3,5-diiodoacetylsalicylate) 4 .
Claim 12
Dependent Claim
21 words
The method according to claim 7 wherein the copper complex of an aryl carboxyic acid is Cu(II) 2 (benzoate) 4 .
Claim 13
Independent Claim
52 words
A method of treating convulsive tremors or convulsive seizures comprising administration to a mammal of a therapeutically effective amount of an organic compound of copper having anticonvulsant activity selected from the group consisting of a copper complex of salicylic acid, a copper complex of a substituted salicylic acid and a mixture thereof.
Claim 14
Independent Claim
52 words
A method of treating convulsive tremors or convulsive seizures comprising administration to a mammal of a therapeutically effective amount of an organic compound of copper having anticonvulsant activity selected from the group consisting of a copper complex of salicylic acid, a copper complex of a substituted salicylic acid and a mixture thereof.
Claim 15
Independent Claim
48 words
A method of treating epilepsy comprising administration to a mammal of a therapeutically effective amount of an organic compound of copper having antiepileptic activity selected from the group consisting of a copper complex of salicylic acid, a copper complex of a substituted salicylic acid and a mixture thereof.
Claim 16
Independent Claim
48 words
A method of treating epilepsy comprising administration to a mammal of a therapeutically effective amount of an organic compound of copper having antiepileptic activity selected from the group consisting of a copper complex of salicylic acid, a copper complex of a substituted salicylic acid and a mixture thereof.
Claim 17
Dependent Claim
76 words
The method according to claim 11 or 12 wherein the copper complex of salicylic acid or a substituted salicylic acid is selected from the group consisting of: (a) Cu(II)(salicylate) 2 ; (b) Cu(II)(4-tertiarybutylsalicylate) 2 .1/2H 2 O; (c) Cu(II)(3,5-diisopropylsalicylate) 2 ; (d) Cu(II)(4-nitrosalicylate) 2 ; (e) Cu(II)(4-aminosalicylate) 2 ; (f) Cu(II)(4-acetylaminosalicylate) 2 ; (g) Cu(II)(salicylate) 2 (pyridine) 2 ; (h) Cu(II)(3,5-ditertiarybutylsalicylate) 2 ; (i) Cu(II)(5-chlorosalicylate) 2 ; (j) Cu(II)(3,5-dibromosalicylate) 2 ; and (k) Cu(II)(3,5-dichlorosalicylate) 2 .
Claim 18
Dependent Claim
18 words
The method according to claim 1, 2, 11 or 12 wherein the organic copper compound is administered intravenously.
Claim 19
Dependent Claim
18 words
The method according to claim 1, 2, 11 or 12 wherein the organic copper compound is administered intraperitoneally.
Claim 20
Dependent Claim
17 words
The method according claim 1, 2, 11 or 12 wherein the organic copper compound is administered subcutaneously.
Claim 21
Dependent Claim
18 words
The method according to claim 1, 2, 11 or 12 wherein the organic copper compound is administered orally.
Claim 22
Dependent Claim
18 words
The method according to claim 1, 2, 11 or 12 wherein the organic copper compound is administered topically.
Claim 23
Dependent Claim
32 words
The method according to claim 1, 2, 11 or 12 wherein the organic copper compound is administered in an amount between about 0.1 to about 100 milligrams per kilogram of body weight.
Claim 24
Dependent Claim
26 words
The method according to claim 1, 2, 11 or 12 wherein the organic copper compound is administered in the form of a solution, suspension or ointment.
Claim 25
Dependent Claim
23 words
The method according to claim 20 wherein the solution, suspension or ointment includes saline, ethylene glycol or a suspending agent like polyoxyethylene glycol.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1991-07-19 | 1992-01-18 | 1992-07-19 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1995-07-19 | 1996-01-18 | 1996-07-19 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1999-07-19 | 2000-01-18 | 2000-07-19 | $7700.00 | Window Closed / Lapsed |